| Hazard Information | Back Directory | [Uses]
CL-242817 is an orally available angiotensin converting enzyme (ACE) inhibitor. CL-242817 inhibits the conversion of angiotensin I to angiotensin II and has blood pressure lowering activity. CL-242817 can also improve Monocrotaline (HY-N0750) induced lung injury. CL-242817 can be used in the study of pulmonary fibrosis and hypertension-related diseases[1]. | [in vivo]
CL-242817 (60 mg/kg, p.o., everyday for six weeks) causes male Wistar rats to fail to gain weight at a normal rate and significantly reduces cardiac function, significantly improves vascular occlusion and monocholinergic injury caused by Monocrotaline (HY-N0750), inhibits ACE activity and reduces hydroxyproline (HP) content in the lungs[1]. | [References]
[1] Molteni, et al. Monocrotaline-induced cardiopulmonary damage in rats: amelioration by the angiotensin-converting enzyme inhibitor CL242817. Proceedings of the Society for Experimental Biology and Medicine 182.4 (1986): 483-493. DOI:10.3181/00379727-182-42370
[2] FM Lai, et al. Some in vitro and in vivo studies of a new angiotensin I‐converting enzyme inhibitor [[S‐(R*), S*]‐1‐[(3‐acetylthio)‐3‐benzoyl‐2‐methylpropionyl]‐L‐proline](CL 242,817) in comparison with captopril. Drug Development Research 3.3 (1983): 261-269. |
|
|